Relmada prices $100M underwritten offering of common stock and pre-funded warrants at $2.20/share

RELMADA THERAPEUTICS, INC.

Priced 40.1M shares of common stock at $2.20/share and pre-funded warrants for 5.3M shares at $2.199/warrant.
Gross proceeds of ~$100M; net proceeds ~$100M after expenses, expected closing Nov 5, 2025.
Investors include Janus Henderson, Ferring Ventures, Squadron Capital, Marshall Wace, Spruce Street, OrbiMed, Columbia Threadneedle, Driehaus.
Company insiders (CEO, CFO, board members) purchasing ~$2.6M in shares at same price.
Proceeds for working capital, clinical studies, product development, and potential acquisitions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.